{
    "clinical_study": {
        "@rank": "164707", 
        "acronym": "FREEDOM", 
        "arm_group": [
            {
                "arm_group_label": "Fidaxomicin", 
                "arm_group_type": "Experimental", 
                "description": "Fidaxomicin with alternating matching placebo"
            }, 
            {
                "arm_group_label": "Vancomycin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to  compare fidaxomicin versus vancomycin for the sustained\n      clinical cure of Clostridium difficile Infection (CDI) in adult patients receiving\n      immunosuppressive therapy."
        }, 
        "brief_title": "A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Clostridium Difficile", 
        "condition_browse": {
            "mesh_term": "Clostridium Infections"
        }, 
        "detailed_description": {
            "textblock": "On Day 1, subjects with diarrhea defined as having three or more unformed bowel movements or\n      >200 mL of unformed stool (for subjects having rectal collection devices) within 24 hours,\n      confirmed by a rapid CDI test (positive for both toxins A & B and glutamate dehydrogenase)\n      to have CDI will be randomized to receive fidaxomicin or vancomycin  (1:1 randomization).\n\n      Subjects will be treated with study medication from Day 1 to Day 10. Assessment for clinical\n      cure (Test of Cure [TOC]) will take place 48 - 72 hours after End of Treatment (EOT).\n      Subjects not meeting the definition of clinical cure at TOC will be defined as treatment\n      failures.\n\n      A stool sample for evaluation of microbial cure will be taken at TOC on Day 12. Subjects\n      meeting the criteria for clinical cure at TOC will be monitored for recurrence until 28 days\n      after TOC (Day 40).\n\n      Treatment of subjects with recurrence of CDI will be at the discretion of the Investigator.\n      Subjects not meeting the criteria for clinical cure at TOC will be followed for safety until\n      Day 40. Further CDI treatment will be at the discretion of the Investigator.\n\n      The strain of Clostridium difficile will be determined for all samples."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  CDI is confirmed by clinical symptoms and rapid CDI test\n\n          -  Subject has not been treated with medication for CDI within the last 10 days\n\n          -  Subject is:\n\n               -  receiving immunosuppressive therapy (chemotherapy) or is undergoing a  stem cell\n                  transplant procedure (defined as the time period from the start of conditioning\n                  prior to transplant until 6 months after infusion of stem cells) for a\n                  hematological malignancy; or\n\n               -  receiving immunosuppressive therapy (chemotherapy) for a solid tumor malignancy\n                  or following solid organ transplantation; or\n\n               -  being treated with immunosuppressive and /or anti-TNF therapy for an\n                  auto-immune disease\n\n          -  Any woman of childbearing potential requires negative serum or urine  pregnancy test\n             before entry to the study\n\n          -  Male and female subjects that are sexually active must agree to practice effective\n             birth control during the study and for 30 days after the end of the study\n\n        Exclusion Criteria:\n\n          -  The subject has experienced more than one previous episode of CDI within the 3 months\n             prior to study inclusion\n\n          -  Taking or requiring to be treated with prohibited medications\n\n          -  Unable to take oral study medication\n\n          -  Female patients that are pregnant, intend to become pregnant or are breastfeeding\n\n          -  History of ulcerative colitis or Crohn's disease\n\n          -  History or diagnosis of toxic megacolon or pseudomembranous colitis\n\n          -  Hypersensitivity to fidaxomicin or any of its components\n\n          -  Hypersensitivity to vancomycin or any of its components"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775397", 
            "org_study_id": "FID-EC-0001", 
            "secondary_id": "2012-000531-88"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fidaxomicin", 
                "description": "capsule", 
                "intervention_name": "Fidaxomicin", 
                "intervention_type": "Drug", 
                "other_name": "Dificlir\u00ae"
            }, 
            {
                "arm_group_label": "Vancomycin", 
                "description": "capsule", 
                "intervention_name": "Vancomycin", 
                "intervention_type": "Drug", 
                "other_name": "Vancocin\u00ae"
            }, 
            {
                "arm_group_label": "Fidaxomicin", 
                "description": "Capsule", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vancomycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Clostridium", 
            "Difficile", 
            "Infections", 
            "Immunosuppression", 
            "Fidaxomicin", 
            "Vancomycin", 
            "Efficacy", 
            "Stem Cells", 
            "Transplantation", 
            "Adult", 
            "Dificid"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "Link to Results on JAPIC", 
            "url": "http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=1067"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "Univ. Klinik f\u00fcr Innere Medizi"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herlev", 
                        "country": "Denmark", 
                        "zip": "2730"
                    }, 
                    "name": "Herlev University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75743"
                    }, 
                    "name": "H\u00f4pital Necker"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75005"
                    }, 
                    "name": "Institut Curie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Charit\u00e9"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45417"
                    }, 
                    "name": "Universit\u00e4tsklinikum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halle", 
                        "country": "Germany", 
                        "zip": "6097"
                    }, 
                    "name": "Universit\u00e4tsklinikum Halle"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koln", 
                        "country": "Germany", 
                        "zip": "50937"
                    }, 
                    "name": "Klinik I f\u00fcr Innere Medizin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11527"
                    }, 
                    "name": "Laiko General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "10675"
                    }, 
                    "name": "General Hospital of Athens"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heraklion", 
                        "country": "Greece", 
                        "zip": "70013"
                    }, 
                    "name": "University Hospital of Crete"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Piraeus", 
                        "country": "Greece", 
                        "zip": "18537"
                    }, 
                    "name": "Metaxa Anticancer Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brzoz\u00f3w", 
                        "country": "Poland", 
                        "zip": "36-200"
                    }, 
                    "name": "Szpital Specjalistyczny w Brzo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08907"
                    }, 
                    "name": "H. U. de Bellvitge"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital 12 de Octubre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "H.U. Gregorio Maranon"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "Denmark", 
                "Finland", 
                "France", 
                "Germany", 
                "Greece", 
                "Hungary", 
                "Italy", 
                "Poland", 
                "Russian Federation", 
                "Spain", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe Ltd.", 
            "last_name": "Associate Director Medical Affairs", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Austria: Federal Office for Safety in Health Care", 
                "Denmark: Danish Medicines Agency", 
                "Finland: Finnish Medicines Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Greece: National Organization of Medicines", 
                "Hungary: National Institute of Pharmacy", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Clinical cure is defined as a subject that at TOC no further CDI therapy is required since completion of study medication, and has either:\n\u22643 unformed bowel movements for two consecutive days\n\u226550% reduction in the number of unformed bowel movements compared to baseline; or\n75% reduction in the volume of liquid stool collected or no longer passing liquid stools (for subjects having rectal collection device)", 
            "measure": "Sustained clinical cure of CDI at day 26", 
            "safety_issue": "No", 
            "time_frame": "Day 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775397"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical cure is defined as a subject that at TOC no further CDI therapy is required since completion of study medication, and has either:\n\u22643 unformed bowel movements for two consecutive days\n\u226550% reduction in the number of unformed bowel movements compared to baseline; or\n75% reduction in the volume of liquid stool collected or no longer passing liquid stools (for subjects having rectal collection device)", 
                "measure": "Clinical Cure of CDI", 
                "safety_issue": "No", 
                "time_frame": "Day 12"
            }, 
            {
                "description": "Clinical cure is defined as a subject that at TOC no further CDI therapy is required since completion of study medication, and has either:\n\u22643 unformed bowel movements for two consecutive days\n\u226550% reduction in the number of unformed bowel movements compared to baseline; or\n75% reduction in the volume of liquid stool collected or no longer passing liquid stools (for subjects having rectal collection device)", 
                "measure": "Sustained Clinical Cure of CDI at day 40", 
                "safety_issue": "No", 
                "time_frame": "Day 40"
            }, 
            {
                "description": "Total viable count of clostridium difficile recovered from fecal specimen is below the limit of detection", 
                "measure": "Microbial Eradication", 
                "safety_issue": "No", 
                "time_frame": "Day 12"
            }, 
            {
                "description": "First of two days with <3 bowel movements per day", 
                "measure": "Resolution of diarrhea", 
                "safety_issue": "No", 
                "time_frame": "Day 12"
            }, 
            {
                "measure": "Use of further CDI therapy required", 
                "safety_issue": "No", 
                "time_frame": "Between Day 10 and Day 12"
            }, 
            {
                "measure": "Number of unformed stools", 
                "safety_issue": "No", 
                "time_frame": "Between Day 10 and Day 12"
            }, 
            {
                "measure": ">50% reduction in number of unformed stools compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 12"
            }, 
            {
                "description": "After TOC, re-establishment of diarrhea to an extent that is greater than the frequency recorded on the last day of study medication", 
                "measure": "Recurrence of CDI", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 and Day 40"
            }, 
            {
                "description": "Time elapsing (days) from TOC to confirmed recurrence of CDI", 
                "measure": "Time to recurrence of CDI", 
                "safety_issue": "No", 
                "time_frame": "Between Day 12 and Day 40"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Cubist Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014", 
        "why_stopped": "Study terminated due to difficulty in enrollment"
    }
}